Kylie Tingley
Overview
Explore the profile of Kylie Tingley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
168
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Howie A, Tingley K, Inbar-Feigenberg M, Mitchell J, Angel K, Gentle J, et al.
Orphanet J Rare Dis
. 2024 Oct;
19(1):393.
PMID: 39443985
Background: To inform the development of a core outcome set (COS) for children and youth with mucopolysaccharidoses (MPS), we aimed to identify all outcomes and associated outcome measurement instruments that...
2.
Abdullah K, Hussain J, Chan E, Tingley K, Ly V, Weese J, et al.
Open Forum Infect Dis
. 2024 Oct;
11(Suppl 2):S146-S155.
PMID: 39415826
The 2022 monkeypox virus (MPXV) outbreaks spurred global public health concern. In response, we undertook a living systematic review of its zoonotic characteristics, including potential reservoirs and susceptible species, transmissibility,...
3.
Iverson R, Taljaard M, Geraghty M, Pugliese M, Tingley K, Coyle D, et al.
BMC Pediatr
. 2024 Jan;
24(1):37.
PMID: 38216926
Background: Generating rigorous evidence to inform care for rare diseases requires reliable, sustainable, and longitudinal measurement of priority outcomes. Having developed a core outcome set for pediatric medium-chain acyl-CoA dehydrogenase...
4.
Tingley K, Smith M, Pallone N, Chakraborty P, Potter B
Healthc Q
. 2022 Apr;
24(SP):81-85.
PMID: 35467516
Building on a study to develop core outcome sets for children with rare inherited metabolic diseases, the purpose of this workshop was to inform the design of longitudinal pediatric registries...
5.
Chow A, Iverson R, Lamoureux M, Tingley K, Jordan I, Pallone N, et al.
BMJ Open
. 2022 Feb;
12(2):e055664.
PMID: 35193919
Introduction: Children with inherited metabolic diseases (IMDs) often have complex and intensive healthcare needs and their families face challenges in receiving high-quality, family centred health services. Improvement in care requires...
6.
Howie A, Tingley K, Inbar-Feigenberg M, Mitchell J, Butcher N, Offringa M, et al.
Trials
. 2021 Dec;
22(1):893.
PMID: 34886877
No abstract available.
7.
Howie A, Tingley K, Inbar-Feigenberg M, Mitchell J, Butcher N, Offringa M, et al.
Trials
. 2021 Nov;
22(1):816.
PMID: 34789302
Background: Mucopolysaccharidoses (MPS) are a group of inherited metabolic diseases characterized by chronic, progressive multi-system manifestations with varying degrees of severity. Disease-modifying therapies exist to treat some types of MPS;...
8.
Vanderhout S, Smith M, Pallone N, Tingley K, Pugliese M, Chakraborty P, et al.
Res Involv Engagem
. 2021 Sep;
7(1):66.
PMID: 34521478
Background: Core outcome sets (COS) are lists of consensus-determined outcomes to be measured and reported in all clinical research studies within a disease area. While including patients and families in...
9.
Pugliese M, Tingley K, Chow A, Pallone N, Smith M, Chakraborty P, et al.
Pediatrics
. 2021 Jul;
148(2).
PMID: 34266901
Background: Evidence to guide treatment of pediatric medium-chain acyl-coenzyme A dehydrogenase (MCAD) deficiency and phenylketonuria (PKU) is fragmented because of large variability in outcome selection and measurement. Our goal was...
10.
Tingley K, Coyle D, Graham I, Chakraborty P, Wilson K, Potter B
Orphanet J Rare Dis
. 2021 Jan;
16(1):26.
PMID: 33436030
Background: For many rare diseases, few treatments are supported by strong evidence. Patients, family members, health care providers, and policy-makers thus have to consider whether to accept, recommend, or fund...